LPAR1 and breast carcinoma: The lysophosphatidic acid receptor 1 (LPA1) inhibitor Debio-0719 (Table 1) induces breast cancer dormancy by reducing proliferative markers such as Ki67 and ERK, while increasing the growth inhibiting pathway p38 [34].